Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough. This article highlights three financially grounded biotech stocks that could potentially benefit from this environment.
The three biotech stocks in focus below are just a small sample, and the wider screen surfaced 87 more businesses with similarly compelling stories that are not covered here. To go straight to the full Biotech Stocks screener and identify which ideas best fit your own criteria, analyze the Biotech Stocks screener.
Overview: Arrowhead Pharmaceuticals develops RNA interference medicines targeting hard to treat cardiometabolic and rare diseases, led by late stage RNAi drug candidates.
Operations: Arrowhead reports US$669 million in revenue from nanotechnology related activity, all generated in the United States.
Market Cap: US$8.2 billion
Arrowhead Pharmaceuticals matters in this Biotech Stocks screen because its RNAi platform is already pushing late stage programs toward conditions with high unmet need, where clinical success can rapidly reshape expectations for future value.
“Although plozasiran’s triglyceride and pancreatitis risk reductions support use in high risk severe hypertriglyceridemia, the decision to buy an expensive Priority Review Voucher and pursue STAR program acceleration pulls forward SHTG launch costs into 2026 and 2027. This could weigh on Arrowhead Pharmaceuticals’ earnings before incremental revenue has time to build.”
What happens to Arrowhead’s long term appeal depends heavily on how one unseen pressure ultimately feeds through to margins and cash needs.
That margin pressure question is exactly what the full narrative for Arrowhead Pharmaceuticals tackles, laying out how Arrowhead Pharmaceuticals’ pipeline, cash runway and partnership options could reshape the risk reward balance.
NasdaqGS:ARWR Revenue & Expenses Breakdown as at Oct 2026
Overview: Supernus Pharmaceuticals develops and sells prescription treatments for central nervous system conditions, with ADHD, epilepsy and Parkinson’s therapies supported by a growing CNS pipeline.
Operations: Supernus Pharmaceuticals generates about US$830 million in pharmaceutical revenue, all from CNS focused medicines sold in the United States.
Market Cap: US$2.4 billion
Supernus Pharmaceuticals fits this Biotech Stocks theme through its focus on CNS medicines, where effective therapies can command meaningful pricing power and long product lives. That context makes the next detail especially important.
“Expanding patient pool for core products Qelbree and GOCOVRI remains a live driver, with Qelbree prescriptions growing faster than the overall ADHD market and adult use now exceeding pediatric use.”
What ultimately matters is how one key shift in the broader CNS portfolio reshapes the balance between future growth potential and financial risk.
To see how that shift could accelerate or stall Supernus Pharmaceuticals’ long term story, read the full narrative for Supernus Pharmaceuticals for what the market might be missing.
NasdaqGM:SUPN Revenue & Expenses Breakdown as at Oct 2026
Overview: Johnson & Johnson is a diversified healthcare group whose Innovative Medicine division develops biotech style prescription therapies across oncology, immunology and other major diseases.
Market Cap: US$644.9 billion
For a biotech focused screen, Johnson & Johnson brings a different angle, giving you exposure to drug discovery and biologics inside a much broader healthcare platform that can help absorb pipeline risks.
“Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA’s loss of exclusivity.”
What happens to Johnson & Johnson’s appeal from here may hinge on how one unresolved pressure ultimately shapes earnings quality and cash generation.
That tension between pressure and potential is exactly what the full narrative for Johnson & Johnson unpacks, showing where Johnson & Johnson’s pipeline could be quietly accelerating beyond headline worries.
NYSE:JNJ Earnings & Revenue History as at Oct 2026
Seeking Alternatives Before The Crowd?
Fresh ideas move first. Stocks can be quietly building momentum, then flying once the crowd catches on. Scan these focused shortlists while the data still matters and position ahead of broader interest.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hormel Foods has seen its share price slide over the past few years, and that drop puts a spotlight on a simple question for investors who focus on fundamentals. Is the current valuation of Hormel stock still in line with the earnings power the business is producing today? Over the past 5 years, the share
Space Exploration Technologies (NASDAQ: SPCX) reported its third-quarter earnings after the market closed on Tuesday, Oct. 20. Ahead of the report, I laid out what I’d be looking for. And, frankly, the latest report was better than I expected in several key ways. Here’s a look at what the company’s Q3 earnings showed. Missed AI’s
Shares of AT&T (NYSE:T) fell 8% on Friday after a new report stoked investors’ fears of a potentially disruptive encroachment by Space Exploration Technologies (NASDAQ:SPCX) into the lucrative U.S. wireless market. Image source: Getty Images. Missed AI’s “Act 1”? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they
Black said Tesla must divulge data on how many customers keep their full self-driving (FSD) subscriptions 3-6 months after the free trial of the technology ends. The comment comes on the heels of Tesla confirming earlier this week that over 75% of deliveries in North America in the third quarter included a sign-up for a
Kulicke and Soffa (KLIC): buy, sell, or hold post Q2 earnings? Over the past six months, Kulicke and Soffa’s stock price fell to $72.89. Shareholders have lost 13.9% of their capital, which is disappointing considering the S&P 500 has climbed by 9.1%. This may have investors wondering how to approach the situation. Is now the
Shares of RingCentral (NYSE:RNG) rose 5% on Friday after the communications software provider raised its full-year free cash flow forecast. Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same
Robinhood (NASDAQ: HOOD) hasn’t announced any plans to launch single-stock perpetual futures on its platform yet, but there seems to be a lot of pent-up demand for them. In a recent Mizuho (NYSE: MFG) survey of over 600 active Robinhood users, 94% of respondents were willing to trade single-stock perpetual futures if they became available.
AT&T (T -7.96%) stock had been on a roll, more than doubling from July 2023 to a closing high of $28.10 on March 27, 2026. However, after a strong start to 2026, AT&T stock has since come under pressure from the potential threat of Space Exploration Technologies (SPCX +1.89%) entering the U.S. mobile market. While
Two of the AI building boom’s biggest suppliers just posted blowout quarters. Wall Street is dumping them anyway. Bloom Energy (BE), whose fuel cells generate power on-site at data centers, said Thursday that sales jumped 138% last quarter and raised its full-year outlook to roughly 122% growth. Comfort Systems (FIX), which installs the cooling and
Bloom Energy (NYSE:BE) delivered another blowout quarter, smashing estimates and growing profits faster than sales. Yet, its stock plunged after earnings and was down more than 12% as of Friday noon. The company sells solid-oxide fuel cell servers that turn natural gas into electricity right at a customer’s site. Artificial intelligence (AI) data centers desperately
Moderna (MRNA) trimmed losses Friday, rebounding from a sharp sell-off in the previous session, as investors digested data from a late-stage trial of its personalized melanoma vaccine. The stock opened lower but climbed into positive territory during the session, a day after plunging more than 17% on Thursday in its worst single-day performance since Aug.
This article first appeared on GuruFocus. Cathie Wood’s ARK Invest bought heavily into Meta Platforms (NASDAQ:META) after the stock’s post-earnings selloff, while reducing exposure to Palantir (NASDAQ:PLTR) and Roblox (RBLX). ARK funds purchased 38,110 Meta shares worth about $24.7 million on Thursday, Oct. 22, after the stock plunged roughly 7% and erased its gains for
Some companies don’t keep their ambitions secret. They swagger onto the stock market and draw plenty of attention with a splashy IPO and big promises (lookin’ at you, Tesla). But some incredibly successful stocks are sleeper hits: They quietly sit on the market doing nothing until one day, bam! Their shares take off like a
Quick Read Bloom Energy posted record Q3 sales of $1.24B and raised guidance a third time, yet free cash flow swung to negative $181M, sending shares down 4%. FuelCell Energy is up 58% year to date while Plug Power is down 30%, with both holding flat today, confirming the selloff is Bloom-specific. Building a portfolio
For questions about this article or underlying research, email help@trefis.com. Cognex (CGNX) stock trades at 52.3 times its earnings over the last twelve months. That multiple is more than twice the 23.0 times for the S&P 500. Buyers at that price are paying today for profit the machine vision company has not yet earned, while
After rising incredibly in the first half of 2026, Intel (NASDAQ:INTC) stock has run into rough weather in recent months. Shares of the semiconductor specialist are down by 31% since the beginning of July. However, Intel stock could get a nice shot in the arm following the release of its third-quarter results on Oct. 29.
The S&P 500 (^GSPC -1.21%) and Nasdaq Composite (^IXIC -2.60%) have recently been experiencing a bout of volatility after repeatedly notching record highs throughout 2026. With stocks coming under pressure, some investors are wondering whether a larger market correction is approaching. Part of the concern stems from elevated bond yields and stubborn inflation. Meanwhile, artificial
This has been a year of immense change for Berkshire Hathaway (NYSE:BRKA)(NYSE:BRKB) and its investors. After more than half a century at the helm, the iconic Warren Buffett retired as CEO on Dec. 31, paving the way for Greg Abel to take over. It took Abel mere months to completely reshape Berkshire’s $364 billion portfolio.
Adient’s updated analysis now points to a slightly lower modeled fair value, with the price target moving from US$29.55 to US$27.64. This shift sits alongside a split in analyst opinion, where some recently trimmed targets but still argue the stock could re-rate if execution, margins, and capital allocation improve. As you read on, you will
Barclays just dropped Q3 2026 numbers into a market that has been marking the stock down for weeks. The shares closed at £4.09 on 22 October, with the price sliding over the past month and quarter even as trailing earnings supported a P/E of 7.8x. That gap between weak sentiment and solid profitability is the
